Search
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedLedipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVorapaxar
go.drugbank.com/drugs/DB09030ApprovedVorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or wi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMiltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalMiltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and ...
Categories: P-glycoprotein substratesNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult pati...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIbrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibruti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigationalOlaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in c...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalUmeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath,...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United Sta...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalOlodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates